Momenta Pharmaceuticals, Inc. (MNTA) Receives $14.44 Average PT from Analysts

Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) has earned a consensus rating of “Hold” from the thirteen ratings firms that are covering the firm, Marketbeat.com reports. Three equities research analysts have rated the stock with a sell recommendation and nine have given a hold recommendation to the company. The average 1 year price target among brokers that have issued a report on the stock in the last year is $14.44.

MNTA has been the topic of a number of research analyst reports. Zacks Investment Research upgraded Momenta Pharmaceuticals from a “hold” rating to a “buy” rating and set a $20.00 target price on the stock in a research report on Wednesday, October 4th. Barclays reiterated an “equal weight” rating and set a $16.00 target price (down from $17.00) on shares of Momenta Pharmaceuticals in a research report on Wednesday, October 4th. BidaskClub downgraded Momenta Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, December 7th. J P Morgan Chase & Co reiterated a “hold” rating and set a $14.00 target price on shares of Momenta Pharmaceuticals in a research report on Thursday, October 5th. Finally, Cowen set a $15.00 price target on Momenta Pharmaceuticals and gave the stock a “hold” rating in a report on Wednesday, November 1st.

Momenta Pharmaceuticals (NASDAQ MNTA) traded up $0.55 on Thursday, reaching $13.60. The company’s stock had a trading volume of 1,983,286 shares, compared to its average volume of 598,954. Momenta Pharmaceuticals has a one year low of $11.85 and a one year high of $19.90.

Momenta Pharmaceuticals (NASDAQ:MNTA) last posted its earnings results on Wednesday, November 1st. The biotechnology company reported ($0.44) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.47) by $0.03. The company had revenue of $24.09 million for the quarter, compared to the consensus estimate of $29.58 million. Momenta Pharmaceuticals had a negative return on equity of 16.20% and a negative net margin of 55.61%. Momenta Pharmaceuticals’s quarterly revenue was down 17.3% compared to the same quarter last year. During the same period in the previous year, the business earned ($0.26) earnings per share. equities analysts predict that Momenta Pharmaceuticals will post -1.16 EPS for the current year.

In other news, Director Elizabeth Stoner sold 5,500 shares of the business’s stock in a transaction on Wednesday, December 13th. The stock was sold at an average price of $13.10, for a total value of $72,050.00. Following the completion of the transaction, the director now directly owns 13,240 shares of the company’s stock, valued at $173,444. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, President Craig A. Wheeler sold 35,667 shares of the business’s stock in a transaction on Thursday, September 28th. The stock was sold at an average price of $19.03, for a total value of $678,743.01. Following the completion of the transaction, the president now directly owns 286,121 shares of the company’s stock, valued at $5,444,882.63. The disclosure for this sale can be found here. Over the last three months, insiders sold 49,506 shares of company stock valued at $861,419. Insiders own 4.40% of the company’s stock.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in MNTA. FMR LLC increased its stake in Momenta Pharmaceuticals by 3.3% in the second quarter. FMR LLC now owns 11,125,193 shares of the biotechnology company’s stock valued at $188,015,000 after purchasing an additional 351,743 shares during the last quarter. BlackRock Inc. increased its stake in Momenta Pharmaceuticals by 7.1% in the second quarter. BlackRock Inc. now owns 9,400,485 shares of the biotechnology company’s stock valued at $158,868,000 after purchasing an additional 626,415 shares during the last quarter. Vanguard Group Inc. increased its stake in Momenta Pharmaceuticals by 4.9% in the second quarter. Vanguard Group Inc. now owns 6,243,767 shares of the biotechnology company’s stock valued at $105,519,000 after purchasing an additional 290,090 shares during the last quarter. State Street Corp increased its stake in Momenta Pharmaceuticals by 8.1% in the second quarter. State Street Corp now owns 2,653,427 shares of the biotechnology company’s stock valued at $44,842,000 after purchasing an additional 197,978 shares during the last quarter. Finally, Palo Alto Investors LLC increased its stake in Momenta Pharmaceuticals by 1.6% in the second quarter. Palo Alto Investors LLC now owns 1,787,576 shares of the biotechnology company’s stock valued at $30,210,000 after purchasing an additional 28,200 shares during the last quarter. 93.45% of the stock is owned by institutional investors.

COPYRIGHT VIOLATION WARNING: This story was first reported by Sports Perspectives and is the property of of Sports Perspectives. If you are accessing this story on another website, it was illegally stolen and republished in violation of United States and international copyright & trademark laws. The original version of this story can be viewed at https://sportsperspectives.com/2017/12/17/momenta-pharmaceuticals-inc-mnta-receives-14-44-average-pt-from-analysts.html.

About Momenta Pharmaceuticals

Momenta Pharmaceuticals, Inc is a biotechnology company. The Company is focused on developing generic versions of drugs, biosimilars and therapeutics for oncology and autoimmune disease. The Company has developed generic version of LOVENOX (enoxaparin sodium injection) and COPAXONE (glatiramer acetate injection).

Analyst Recommendations for Momenta Pharmaceuticals (NASDAQ:MNTA)

Receive News & Ratings for Momenta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Momenta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply